TIGIT and neoplasm: The phase II CITYSCAPE trial presented substantial response rates to the TIGIT inhibitor tiragolumab (MTIG7192A, RG-6058) plus atezolizumab only in patients with non-small cell lung cancer as well as programmed death-ligand 1 (PD-L1) tumor proportion scores of 50% or greater [13], suggesting that blockade of the TIGIT checkpoint receptor combined with other treatments deserves further study.